MedTrace Logo

Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy

NCT04076449 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2019-09-04

No results posted yet for this study

Summary

Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion, suggesting an inadequate treatment and evaluation of the epileptogenic zone or network. Iron deposition in cerebral cavernous malformations has been postulated to play an important role in triggering CRE. Quantitative susceptibility mapping (QSM), as an optimal in vivo imaging technique to quantify iron deposition, is employed to analyze the iron quantity in CCM patients with epilepsy and further combined with brain structural and connectome analysis, to describe the difference between CCMs with and without epilepsy. In vivo biomarkers predicting CRE risk in CCM natural history and CRE control outcome after CCM surgical resection will be further identified to improve management strategy.

Conditions

  • Cavernous Malformation, Cerebral
  • Cavernous Angioma
  • Cavernous Hemangioma
  • Cavernous Hemangioma of Brain
  • Seizures
  • Seizures, Epileptic
  • Epilepsy

Sponsors & Collaborators

  • Peking University International Hospital

    collaborator OTHER

  • yuanli Zhao

    lead OTHER

Principal Investigators

  • Li Ma, MD, PhD · Beijing Tiantan Hospital

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-03
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04076449 on ClinicalTrials.gov